Photo taken from: Yüksel Ürün/X
Jan 6, 2024, 23:03
Yüksel Ürün: BEATcc Trial
Yüksel Ürün, Professor at the Department of Medical Oncology, Ankara University School of Medicine, recently posted on X/Twitter:
“BEATcc Trial:
– Dual primary endpoints: Progression-free survival & overall survival.
– Improved outcomes: Atezolizumab group showed better PFS (13.7 vs 10.4 months) & OS (32.1 vs 22.8 months).
– Atezo/Beva/chemo could redefine first-line treatment for metastatic/recurrent cervical cancer.
Reminder: The most effective way to prevent cervical cancer is screening and HPV vaccination.”
Read further.
Source: Yüksel Ürün/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 07:59
Dec 22, 2024, 07:55
Dec 22, 2024, 07:44
Dec 22, 2024, 07:35
Dec 22, 2024, 07:32
Dec 22, 2024, 07:25
Dec 22, 2024, 07:16
Dec 22, 2024, 07:01